Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Transformation to Small-Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR-Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report.

Created on 04 Nov 2026

Authors

Bingyu Huang, Tao Lu, Ruping Hong, Xiaoyan Liu, Xiaoxing Gao, Yan Xu, Minjiang Chen, Wei Zhong, Mengzhao Wang, Jing Zhao

Published in

Thoracic cancer. Volume 17. Issue 21.

Abstract

This case exemplifies stepwise histological transformations of an initially EGFR-mutant lung adenocarcinoma driven by tumor lineage plasticity under therapeutic pressure. Initial resistance to osimertinib manifested as transformation to combined small-cell lung carcinoma, associated with concurrent TP53/RB1 co-inactivation and the acquisition of an epidermal growth factor receptor (EGFR) C797S mutation. Subsequent progression after chemotherapy featured a rare sarcomatoid transformation, with the tumor retaining the original EGFR Exon 19 deletion, supporting clonal evolution. This phenotypic shift, indicative of epithelial-to-mesenchymal transition (EMT), may have been associated with PTEN loss and potential activation of the PI3K/AKT/mTOR pathway. The serial emergence of neuroendocrine and sarcomatoid phenotypes underscores the critical need for rebiopsy to guide therapy and highlights the profound adaptability of EGFR-mutant tumors, which remain a major therapeutic challenge.

PMID:
42977475
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement